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Here, we describe the in vitro and in vivo effects of (4R,5S)-2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide (E1R), a
novel positive allosteric modulator of sigma-1 receptors.
EXPERIMENTAL APPROACH
E1R was tested for sigma receptor binding activity in a [3H](+)-pentazocine assay, in bradykinin (BK)-induced intracellular Ca2+
concentration ([Ca2+]i) assays and in an electrically stimulated rat vas deferens model. E1R’s effects on cognitive function were
tested using passive avoidance (PA) and Y-maze tests in mice. A selective sigma-1 receptor antagonist (NE-100), was used to
study the involvement of the sigma-1 receptor in the effects of E1R. The open-field test was used to detect the effects of E1R
on locomotion.
KEY RESULTS
Pretreatment with E1R enhanced the selective sigma-1 receptor agonist PRE-084’s stimulating effect during a model study
employing electrically stimulated rat vasa deferentia and an assay measuring the BK-induced [Ca2+]i increase. Pretreatment
with E1R facilitated PA retention in a dose-related manner. Furthermore, E1R alleviated the scopolamine-induced cognitive
impairment during the PA and Y-maze tests in mice. The in vivo and in vitro effects of E1R were blocked by treatment with the
selective sigma-1 receptor antagonist NE-100. E1R did not affect locomotor activity.
CONCLUSION AND IMPLICATIONS
E1R is a novel 4,5-disubstituted derivative of piracetam that enhances cognition and demonstrates efficacy against
scopolamine-induced cholinergic dysfunction in mice. These effects are attributed to its positive modulatory action on the
sigma-1 receptor and this activity may be relevant when developing new drugs for treating cognitive symptoms related to
neurodegenerative diseases.
Abbreviations
BK, bradykinin; [Ca2+]i, intracellular calcium ion concentration; E1R, (4R,5S)-2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-
yl)-acetamide; NE-100, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine hydrochloride; PA, passive
avoidance; PB-28, 1-cyclohexyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazine dihydrochloride;
PRE-084, 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate hydrochloride
BJP British Journal ofPharmacology
DOI:10.1111/bph.12506
www.brjpharmacol.org
British Journal of Pharmacology (2014) 171 761–771 761© 2013 The British Pharmacological Society
Introduction
The sigma receptor was first identified as an opiate receptor
subtype (Martin et al., 1976). More than two decades ago, this
separate receptor class was found to be expressed in both the
periphery and CNS (Su et al., 1988; Quirion et al., 1992;
Hanner et al., 1996). Later, the sigma receptor was found to
consist of two pharmacologically distinct subtypes, namely
the sigma-1 and sigma-2 receptors (Hellewell et al., 1994).
Although sigma-1 receptors are localized in peripheral
organs, they are expressed most abundantly in the CNS,
where they participate in various cellular functions, includ-
ing inositol 1,4,5-trisphosphate receptor-mediated Ca2+ sig-
nalling, ion channel firing, protein kinase localization and
activation, cellular redox homeostasis, neurotransmitter
release, inflammation, cellular differentiation, neuronal sur-
vival and synaptogenesis (Matsuno et al., 1993; Hayashi and
Su, 2007; Su et al., 2010; Hayashi et al., 2011). Accumulating
evidence suggests that the sigma-1 receptor plays an impor-
tant role in the pathophysiology of many neurological and
psychiatric disorders, such as Alzheimer’s disease, amnesia,
pain, depression, schizophrenia, stroke and addiction
(Maurice and Su, 2009; Hayashi et al., 2011; Niitsu et al.,
2012). These findings indicate that the sigma-1 receptor may
be an emerging CNS drug target.
Activity at sigma-1 receptors has been identified in several
established CNS drugs and newly synthesized compounds
(Cobos et al., 2008; Su et al., 2010). Both agonists and antago-
nists of sigma-1 receptors have been studied in an attempt to
elucidate their possible pharmacological applications, which
mainly involve learning and memory processes, depression
and anxiety, schizophrenia, analgesia and some effects caused
by certain drugs of abuse (Maurice and Lockhart, 1997;
Monnet and Maurice, 2006; Cobos et al., 2008; Banister and
Kassiou, 2012). For example, the antidepressant fluvoxamine
is a selective 5-HT reuptake inhibitor that possesses a high
affinity for sigma-1 receptors (Narita et al., 1996). In addition,
donepezil is the most widely prescribed drug for Alzheimer’s
disease; it also binds to sigma receptors in the brain and
occupies numerous sigma-1 receptors in the human brain at
therapeutic doses (Ishikawa et al., 2009). Sigma-1 ligands
have demonstrated anti-amnesic actions in many studies of
cholinergic hypofunction induced by pharmacological cho-
linergic receptor blockade (Earley et al., 1991; Matsuno et al.,
1994), centrally administered neurotoxic agents [including
β25–35-amyloid peptides (Maurice et al., 1996; 1998), ibotenic
acid (Senda et al., 1998)] and intraventricularly injected
192IgG-saporin (a selective immunotoxin; Antonini et al.,
2009). In addition, sigma-1 receptor ligands dose-
dependently increased the extracellular acetylcholine level in
rats’ frontal cortices and hippocampi while leaving the stria-
tum unaffected. Such absence of increased striatal acetylcho-
line levels after administering sigma-1 receptor agonists
might explain why these drugs do not display the undesired
side effects that are frequently observed after administering
acetylcholinesterase inhibitors (Matsuno et al., 1992; 1993;
van Waarde et al., 2011). During clinical studies, some
sigma-1 receptor agonists, including fluvoxamine, donepezil
and neurosteroids, improved the cognitive impairment and
clinical symptoms associated with neuropsychiatric diseases
(Silver and Shmugliakov, 1998; Kunitachi et al., 2009; Marx
et al., 2009; Niitsu et al., 2012). Recently, we described a novel
compound called E1R ((4R,5S)-2-(5-methyl-2-oxo-4-phenyl-
pyrrolidin-1-yl)-acetamide; Figure 1), an enantiomer of
4,5-disubstituted piracetam (2-(5-methyl-2-oxo-4-phenyl-
pyrrolidin-1-yl)-acetamide; Kalvins et al., 2011; Veinberg
et al., 2013). Its nootropic activity prompted further research
into its molecular mechanisms of action and E1R was
screened against a commercially available panel of 77
radioligand-binding assays, which provided evidence for the
sigma receptor modulatory activity of E1R.
In the present study, we characterized the mechanism of
action of E1R on [3H](+)-pentazocine binding, on the brady-
kinin (BK)-induced increase in intracellular Ca2+ concentra-
tion ([Ca2+]i) and on the function of peripheral sigma-1 and
sigma-2 receptors, using the electrically stimulated rat vas
deferens. The effects of E1R on cognition and locomotion
were evaluated using passive avoidance (PA), Y-maze and
open-field tests. Because sigma-1 receptor agonists potently
modulate acetylcholine release (Matsuno et al., 1994; van
Waarde et al., 2011), we used scopolamine-induced amnesia
as an experimental model for the memory impairment
caused by cholinergic dysfunction. The rota-rod, traction and
cylinder tests were used to evaluate the influence of E1R on
muscle strength and coordination. The results of these tests
indicated that the cognition-enhancing properties of E1R




All animal care and experimental procedures complied with
the guidelines reported in EU Directive 2010/63/EU and with
local laws and policies; all of the procedures were approved
by the Latvian Animal Protection Ethical Committee of Food
and Veterinary Service in Riga, Latvia. Studies involving
animals are reported in accordance with the ARRIVE guide-
lines (Kilkenny et al., 2010; McGrath et al., 2010). We used a
total of 255 ICR male mice in the PA test, 40 in the open-field
test, 25 in the muscle strength and coordination tests, 76
Figure 1
Structure of E1R.
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Balb/c male mice in the Y-maze test, 6 Wistar rats in the
radioligand-binding assays and 5 Wistar rats in the isolated
vas deferens mode. Male ICR and Balb/c mice weighed
23–25 g, while Wistar rats weighed 220–250 g (Laboratory
Animal Breeding Facility, Riga Stradins University, Riga,
Latvia); all animals were housed under standard conditions
(21–23°C, 12 h light–dark cycle) with unlimited access to
standard food (Lactamin AB, Mjölby, Sweden) and water.
Radioligand-binding assays
High-throughput profile. E1R was profiled in a commercially
available panel of 77 radioligand-binding assays (CEREP, Poi-
tiers, France). The molecular receptor nomenclature used
throughout this paper conforms to the BJP’s Concise Guide to
Pharmacology (Alexander et al., 2013). A specific list of the
assays performed with E1R is documented in the Results
section of this paper, and further details regarding the
methods used to conduct each assay are available from
at http://www.cerep.fr/cerep/users/pages/catalog/profiles/
DetailProfile.asp?profile=2118.
[3H](+)-pentazocine binding assay. Binding experiments were
carried out in the crude synaptosome fraction, obtained from
Wistar rats, as described previously (Cobos et al., 2006). Mem-
brane fraction aliquots were diluted with incubation buffer
(50 mM Tris-HCl, pH 7.4) to reach a final protein concentra-
tion of 4–7 mg·mL−1. E1R and PRE-084 were dissolved in
saline, while haloperidol was dissolved in dimethyl sulfoxide
at a concentration of 10 mM as stock solutions. Stock solu-
tions were diluted with incubation buffer to the required
concentrations (0.1 nM–100 μM). Dilutions at 1:1000 (v/v)
from the stock [3H](+)-pentazocine solution were prepared
using deionized water. The binding assay buffer consisted of
60 μL of incubation buffer, 100 μL membrane aliquots, 20 μL
of the tested drugs or incubation buffer for the control and
20 μL [3H](+)-pentazocine. Before radioligand was added,
membranes were incubated together with tested compounds
for 10 min at room temperature. Non-specific binding was
assessed by adding haloperidol (10 μM). The samples were
incubated for 150 min at 30°C. The bound and free radioli-
gands were separated by rapid filtration under a vacuum
using Millipore GF/B filter paper (Merck Millipore, Billerica,
MA, USA). The filters were washed three times with 0.25 mL
of 10 mM Tris (pH 8.0, 4°C). The radioactivity in samples was
measured with a liquid scintillation counter Wallac
MicroBeta TriLux (PerkinElmer, Waltham, MA, USA) with a
60% efficiency. Each experiment was repeated at least three
times and each assay was conducted in duplicate.
Measurement of the BK-induced increase in
the [Ca2+]i
NG-108 cells were purchased from LGC Standards AB, Boras,
Sweden. Cells were cultured and differentiated with the
procedure described previously (Yamada et al., 2006). The
changes in [Ca2+]i were studied using a Fluo-4 NW Calcium
Assay Kit (Invitrogen, Stockholm, Sweden) according to the
manufacturer’s instructions. The NG-108 cells were loaded
with Fluo-4 NW for 45 min. The Fluo-4 NW-loaded cells were
pre-incubated with 10 μM E1R, 2 μM PRE-084 or both in the
dark at room temperature for 15 min. Pre-incubation with
deionized water was used as a control. Subsequently, 1 μM BK
was added to the wells to increase the [Ca2+]i. The changes in
[Ca2+]i were measured using the fluorescence emitted at
516 nm, which was generated by excitation at 494 nm, using
the Fluoroskan Ascent Microplate Fluorometer (Thermo Lab-
systems, Helsinki, Finland). 40 μM NE-100 was used as the
positive control and was pre-incubated with the cells for
20 min before the measurements were taken.
The selected compounds were diluted with deionized
water. Cell survival was determined indirectly by measuring
the total cellular protein via the Kenacid Blue R (KBR) dye-
binding method (Clothier, 1995). The obtained relative fluo-
rescence units (RFU) were standardized to the total cellular
protein of each sample (RFUs = RFU OD(KBR)−1). The responses
to the BK-induced [Ca2+]i changes with or without pre-
incubation with the test compounds were calculated as the
per cent increase in the basal RFUs.
Sigma receptor activity model of isolated
vas deferens
Wistar rats were decapitated. Both vasa deferentia were
excised and immersed in an ice-cold Krebs–Henseleit buffer
solution (content in mmol·L−1: NaCl 118.0, KCl 4.75, CaCl2
2.52, MgCl2 1.64, NaHCO3 24.88, K2HPO4 1.18, glucose 10.0
and EDTA 0.05). Cleaned proximal portions of each vas def-
erens (∼15 mm) were mounted in 50 mL organ baths and
incubated in a Krebs–Henseleit buffer solution that was main-
tained at 32°C and bubbled with 95% CO2 and 5% O2 (Pubill
et al., 1998). The passive tension was fixed at 1 g, and the
buffer solution in the organ bath was changed every 15 min.
After a 60 min adaptation period, the isolated vasa deferentia
were stimulated with an electrical current (0.1 Hz, pulse dura-
tion of 1 ms 50 V). When the stimulation produced a stable
contraction amplitude, cumulative doses (from 1 to 100 μM)
of the sigma-1 receptor agonist PRE-084 were added. After
reaching the plateau contraction amplitude, at the highest
studied PRE-084 concentration (100 μM), the electrical stimu-
lation was turned off, and each isolated vas deferens was
washed several times with a Krebs–Henseleit buffer solution.
After 30 min, electrical stimulation was resumed under the
same parameters. When the electrical current induced a
stable contraction amplitude, E1R was added to each isolated
vas deferens at a concentration of 10 μM. After 10 min of
electrical stimulation, cumulative doses of PRE-084 were
added. To test for sigma-2 receptor activity, a selective
sigma-2 receptor agonist PB-28; at concentrations ranging
from 1 to 10 μM was used in a similar experimental set-up.
Responses to selective sigma receptor agonists before and
after the addition of the test compound were calculated as the
percentage increase in the baseline contraction amplitude.
E1R dosing in vivo
In the PA test, the animals received an i.p. injection of E1R at
doses of 0.1, 1 and 10 mg·kg−1 60 min before training. The
effect of E1R on scopolamine-induced cognitive deficits was
assessed using the PA test, where E1R was administered i.p. at
doses of 1, 5 and 10 mg·kg−1 60 min before the training
session and scopolamine was administered s.c. at a dose of
0.3 mg·kg−1 20 min after the E1R injection. NE-100 was
administered i.p. at a dose of 2 mg·kg−1 20 min before E1R,
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which was administered at a dose 5 mg·kg−1 60 min before the
acquisition trial in the scopolamine-induced cognitive deficit
test. Prior to Y-maze test, the animals received an i.p.
injection of E1R at a dose of 10 mg·kg−1 60 min before the
experiment, scopolamine was administered s.c. at a dose
of 0.5 mg·kg−1 20 min after E1R injection, and NE-100 was
administered i.p. at a dose of 2 mg·kg−1 20 min prior to E1R.
In the open-field test, E1R was administered i.p. at doses of 1,
10 and 100 mg·kg−1 30 min prior to experimentation. The
control groups received an i.p. injection of saline. In the
rota-rod, traction and chimney tests, measurements were
made before i.p. administration of E1R at doses of 50, 100,
250, 500 and 630 mg·kg−1 and again at 30, 60, 120, 180 and
240 min after i.p. administration. All drugs were dissolved in
0.9% physiological saline (Fresenius Kabi, Warszawa, Poland)
during the in vivo experiments.
Behavioural experiments
PA test. The PA test was performed as previously described
(Zvejniece et al., 2011). Briefly, on the training day, each
mouse was individually placed in the light compartment of
an apparatus with no access to the dark compartment and
allowed to explore for 60 s (Ugo Basile, Comerio, Italy). After
this time, the sliding door (4 × 4 cm) was automatically
opened and the mouse was allowed to cross over into the dark
compartment. Upon entering the dark compartment, the
mouse received a shock of 0.1 mA for 3 s, the door was closed,
and the mouse was returned to its home cage after 20 s. A
retention test was performed on the next day (24 h later)
without any shock. The time taken to enter the dark
compartment was recorded as the retention latency. The
maximum retention latency was set at 540 s.
Scopolamine-induced cognitive deficits in the PA test. The test
was performed in essentially the same manner described in
the PA test, with the exception that mice received a shock of
0.4 mA for 3 s.
Scopolamine-induced cognitive deficits in the Y-maze test.
Working memory performance was assessed by recording
spontaneous alternation behaviour in a Y-maze, as previously
described (Yamada et al., 1999). The experiment was con-
ducted in a dim red-lit room. The mice were individually
placed at the end of one arm in a symmetrical Y-shaped
runway (arm length 35 cm, width 5 cm, height 21 cm) and
allowed to explore the maze for 5 min. An alternation was
defined as consecutive entries into all three arms. The total
number and sequence of the arm entries were manually
recorded, and the percentage of alternation was calculated
(Yamada et al., 1999).
Open-field test. To test the effects of E1R on locomotor activ-
ity, the open-field test was used. The test apparatus was a
square arena (44 × 44 cm) with a black floor. The mice were
gently placed in the centre of the field, and behavioural
parameters were recorded using the EthoVision video track-
ing system (version 3.1., Noldus, Wageningen, The Nether-
lands). The distance moved (cm·4 min−1) and velocity (cm·s−1)
were recorded. Testing consisted of five successive 4 min ses-
sions that started 30, 60, 120, 180 and 240 min after com-
pound administration.
Muscle strength and coordination. A rota-rod test was used to
measure motor coordination (Model 7600, Ugo Basile). One
day before the experiment, the animals were trained on the
apparatus. On the day of the experiment, the animals were
placed on a rota-rod (16 rpm), and the number of animals
that fell off of the rota-rod within the 180 s session was
recorded. The effect of drugs on motor performance was also
tested using the chimney test (Dambrova et al., 2008). In this
test, mice had to climb backwards up a Pyrex glass tube
(30 cm length, 3 cm inner diameter). Mice successfully reach-
ing the 20 cm mark within 30 s were selected for further
testing. The effect of drugs on muscle strength was examined
using the traction test. Hence, the forepaws of a mouse were
placed on a firmly fixed horizontal stick. The untreated mice
grasped the stick with both forepaws and, when allowed to
hang free, placed at least one hind foot on the stick within
5 s. Inability to perform this task was scored as a failure of
traction.
Data analyses
The results are expressed as means ± SEM. The electrical
current-induced contraction amplitudes of the isolated vasa
deferentia were analysed using two-way repeated measures
ANOVA followed by Bonferroni post hoc testing. Data for the
BK-induced increase in [Ca2+]i were analysed using one-way
ANOVA followed by Tukey’s test. For the PA and Y-maze experi-
ments, data were analysed using one-way ANOVA followed by
the Newman–Keuls test. For dose-related effects of E1R on the
scopolamine-induced impairment of PA experiments, statis-
tical analysis was performed using one-way ANOVA followed by
the Mann–Whitney U-test. P-values less than 0.05 were con-
sidered statistically significant. The statistical calculations
were performed using the GraphPad Prism 3.0 software
package (GraphPad Software, Inc., La Jolla, CA, USA). The
ED50 values were obtained by probit analysis.
Materials
E1R was prepared at the Latvian Institute of Organic Synthe-
sis according to a previously published procedure (Kalvins
et al., 2011; Veinberg et al., 2013). Haloperidol was purchased
from Alfa Aesar, Karlsruhe, Germany. Bradykinin, NE-100,
PRE-084 and PB-28 were purchased from Tocris Bioscience,
Bristol, UK. (-)Scopolamine hydrochloride was obtained from
Fluka (St. Louis, MO, USA). [3H](+)-pentazocine specific activ-
ity 33.9 Ci·mmol−1 was purchased from American Radiola-
beled Chemicals, St. Louis, MO, USA.
Results
In vitro selectivity profiling of E1R
The pharmacological profiling of E1R against various possible
targets was performed using a commercially available
radioligand-binding assay screen that was performed by
CEREP (see Methods). E1R at a 10 μM concentration had little
or no activity in 77 radioligand displacement assays that
included numerous ion channel, GPCR and CNS transporter
targets (Supporting Information Table S1). The only target for
E1R (inhibition or enhancement of radioligand binding
exceeding 20%) was the sigma receptor. Here 10 μM E1R did
BJP L Zvejniece et al.
764 British Journal of Pharmacology (2014) 171 761–771
not displace the radioligand, but instead increased the spe-
cific binding of a non-selective radioligand ([3H]1,3-di(2-
tolyl)guanidine) for the sigma receptor by 38% in Jurkat cells
(Supporting Information Table S1). In the same assay, the
sigma receptor antagonist haloperidol inhibited the binding
of the radioligand with an IC50 = 43 nM.
Action of E1R on [3H](+)pentazocine binding
Unlike the selective sigma-1 receptor agonist PRE-084 (IC50 =
192 nM) or the non-selective sigma receptor antagonist
[haloperidol (IC50 = 0.5 nM)], E1R did not displace [3H](+)-
pentazocine from the sigma-1 receptors (Figure 2). As seen
in Figure 2, E1R did not modulate binding of [3H](+)-
pentazocine in this binding assay. It should be noted that we
also failed to demonstrate sigma-1 receptor modulatory effect
for phenytoin in this assay (data not shown).
Effects of E1R on the BK-induced increase of
[Ca2+]i in NG-108 cells
The selective sigma-1 receptor agonist PRE-084 at 2 μM
enhanced the BK-induced [Ca2+]i increase in NG-108 cells and
E1R (10 μM) also enhanced the increase of [Ca2+]i (Figure 3,
F7,75 = 94.15, P < 0.0001). Moreover, the effects of PRE-084
on the [Ca2+]i changes were potentiated three times after
pre-incubation with E1R (Figure 3, P < 0.001). The effects
of PRE-084, E1R and their combination were antagonized by
administering a selective sigma-1 receptor antagonist,
NE-100, at 40 μM (Figure 3, F7,75 = 94.15, P < 0.0001).
Effects of E1R on sigma-1 and sigma-2
receptors in the rat isolated vas deferens
The addition of cumulative doses of E1R did not influence the
contractions of electrically stimulated rat vasa deferentia
(Figure 4A) but these contractions were potentiated in the
presence of the sigma-1 receptor agonist PRE-084 (100 μM)
(Figure 4A,C; F4,29 = 38.35, P < 0.0001). Pre-incubation of vasa
deferentia with a 10 μM solution of E1R for 10 min prior to
the addition of PRE-084 significantly increased the intensity
of the contractions [Figure 4A,C; a two-way repeated ANOVA
confirmed that the group (F1,10 = 6.94, P < 0.05), dose (F4,40 =
64.07, P < 0.0001) and dose-by-group interactions (F4,40 =
3.18, P < 0.05) were the main effects]. The electrically stimu-
lated contractions of rat vasa deferentia were also increased
by the sigma-2 receptor agonist PB-28 (Figure 4B,D), but pre-
treatment with E1R did not affect this response to PB-28
[Figure 4B,D; in a two-way repeated ANOVA, dose (F4,24 = 15.73,
P < 0.0001) was a main effect, but there were no effects of the
group (P > 0.05) or dose-by-group interactions (P > 0.05)].
Effects of E1R on cognition in the PA test
The PA test was used to examine the cognition-enhancing
activity of E1R in mice. The retention latency, which was
measured as response to a foot shock of 0.1 mA for 3 s, in
control animals was 76 ± 16 s. Treatment with E1R signifi-
cantly improved cognitive function in a dose-related manner
(F3,64 = 4.363, P < 0.01). As shown in Figure 5A, treatment with
E1R at doses of 1 and 10 mg·kg−1 increased retention latency
by 194 and 211%, respectively, compared with the control
group. There were no differences in dark compartment
entrance during training between the control and E1R-
treated groups (data not shown).
The PA test was also used to detect the effects of E1R on
scopolamine-induced memory impairment. Pretreatment
with scopolamine markedly reduced the control (saline injec-
tion) retention latency (Figure 5B, P < 0.0001). E1R, at 5 and
10 mg·kg−1, increased the retention latency of scopolamine-
treated animals, by 237 and 209%, respectively (F4,89 = 6.91,
P < 0.0001). Treatment with the selective sigma-1 receptor
Figure 2
The effects of E1R and sigma receptor ligands on the binding of
[3H](+)-pentazocine to a sigma-1 receptor. Synaptosomes from rat
brains were incubated with 1.5 nM [3H](+)-pentazocine at 30°C for
150 min. Haloperidol (10 μM) was used to define non-specific
binding. The data represent at least three experiments performed in
duplicate.
Figure 3
The effect of E1R, the selective sigma-1 receptor agonist PRE-084
and antagonist NE-100, as well as their combinations on 1 μM
BK-induced [Ca2+]i increase in NG-108 cells. The cells were pre-
incubated with 10 μM E1R, 2 μM PRE-084 or both in the dark at
room temperature for 15 min. 40 μM NE-100 was pre-incubated
with the cells for 20 min before the measurements were taken.
Changes in the [Ca2+]i were calculated as the percentage increase of
the basal RFUs. Each column represents the mean ± SEM. *P < 0.05
versus BK, #P < 0.05 versus PRE-084, $P < 0.05 versus E1R, &P < 0.05
versus E1R and PRE-084 combination.
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antagonist NE-100 inhibited the cognition-enhancing activ-
ity of E1R at a dose of 5 mg·kg−1 (Figure 5C, F4,96 = 14.45, P <
0.0001). The training latencies did not differ between the
saline control, the scopolamine- and the E1R-treated groups
(data not shown).
Effects of E1R on cognition in Y-maze test
The Y-maze test was used to detect effects of E1R on
scopolamine-induced impairment of working memory
(Figure 6). The spontaneous alternation behaviour in the
control animals was reduced by pretreatment with scopola-
mine (P < 0.001). As shown in Figure 6, treatment with E1R
(10 mg·kg−1) increased the spontaneous alternation behav-
iour, compared with the scopolamine-treated group (F4,71 =
6.19, P < 0.0002). Treatment with the selective sigma-1 recep-
tor antagonist NE-100 (2 mg·kg−1) significantly inhibited the
enhancement of working memory of E1R at a dose of
10 mg·kg−1 (P < 0.05).
Effects of E1R on locomotion
The open-field test was used to determine the influence of
the compounds on locomotor activity. Doses of E1R up to
100 mg·kg−1 did not affect the distance moved, compared
with the control animals [Table 1, two-way repeated ANOVA,
main effect of group (F3,28 = 6.86, P > 0.05), time (F4,112 = 49.99,
P < 0.0001) and time-by-group interaction (P > 0.05)].
Effects of E1R on muscle strength and
coordination
In the rota-rod, chimney and traction tests, an inhibitory
activity of E1R on muscle function was observed, with the
following ED50 values (with ED16–ED84): 453 (398–516), 349
(199–611) and 595 (409–866) mg·kg−1 respectively.
Discussion
In the present study, we characterized a novel enantiomer of
4,5-disubstituted piracetam, E1R, as both a positive allosteric
modulator of the sigma-1 receptor and a cognition enhancer.
The compound had no effect on locomotor activity, muscle
tone or coordination at doses up to 200 mg·kg−1. Therefore,
E1R was found to be free of potential motor side effects. The
sigma receptor target site was the only site that E1R was




Sigma receptor activity assay in the electrically stimulated rat isolated vas deferens. (A,C) Effects of E1R (10 μM) on contractions potentiated by
the selective sigma-1 receptor agonist (PRE-084). The results are expressed as the percentage of control contraction height and represent the
means ± SEM; n = 6. (B,D) Effects of E1R (10 μM) on the selective sigma-2 receptor agonist (PB-28) in electrically stimulated rat vasa deferentia.
The results are expressed as the percentage of control contraction height and represent the means ± SEM; n = 4. *P < 0.05 versus PRE-084
treatment (as analysed using two-way repeated ANOVA followed by the Bonferroni post hoc test), #P < 0.05 versus the baseline concentration.
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assays conducted, including a number of ion channels,
GPCRs and CNS transporter targets. Our in vitro assays
revealed that E1R did not bind directly to the sigma-1 recep-
tors, but rather acted as a positive allosteric modulator. It
should be noted that E1R enhanced the binding of an non-
selective sigma receptor radioligand [3H]1,3-di(2-tolyl)
guanidine but we failed to demonstrate any modulatory
effects of E1R on sigma-1 receptors, using the selective
sigma-1 receptor radioligand, [3H](+)-pentazocine binding
assay. However, E1R potentiated the contractions of rat vasa
deferentia in the presence of the sigma-1 receptor agonist
PRE-084 and not in the presence of the sigma-2 receptor
agonist PB-28 (Figure 4). In addition, E1R enhanced the effect
of PRE-084 on the BK-induced [Ca2+]i increase (Figure 3) thus
confirming the positive allosteric modulation of sigma-1
receptors in vitro.
Several lines of evidence have suggested that activation of
sigma-1 receptors ameliorates cognitive deficits in animal
models of cholinergic dysfunction that mimic the cognitive
symptoms of Alzheimer’s disease (Earley et al., 1991; Matsuno
et al., 1994; Maurice et al., 1998; Antonini et al., 2009;
Maurice and Su, 2009; Hayashi et al., 2011). In addition,
sigma-1 receptor agonists act as potent modulators of acetyl-
choline release (Matsuno et al., 1993; van Waarde et al.,
2011). Because our in vitro studies identified E1R as a positive
allosteric modulator of the sigma-1 receptor, we hypothesized
that E1R might protect against scopolamine-induced cogni-
tive deficits. E1R successfully alleviated the scopolamine-
induced cognitive impairment assessed during the PA and
Y-maze tests in mice. The effects of E1R were antagonized by







(A) Dose-related effects of E1R on PA retention in mice. E1R (0.1, 1
and 10 mg·kg−1, i.p.) was administered 60 min before the training
session. The retention test was performed 24 h later. The vertical bars
represent the means ± SEM; n = 15–18. *P < 0.05 and **P < 0.01
versus the saline group. (B) Dose-related effects of E1R on the
scopolamine-induced impairment of PA retention in mice. The mice
were injected with E1R (1, 5 and 10 mg·kg−1, i.p.) 60 min before the
training session. Scopolamine (0.3 mg·kg−1, s.c.) was administered
40 min prior to the training session. The vertical bars represent the
means ± SEM; n = 17–20. (C) The effect of E1R (5 mg·kg−1) was
antagonized by the administration of the selective sigma-1 receptor
antagonist NE-100 (2 mg·kg−1) Each column represents the means ±
SEM; n = 20–25. #P < 0.05 of the scopolamine-treated group versus
the saline control group, *P < 0.05 versus the scopolamine-treated
group, and $P < 0.05 versus the E1R-treated group.
Figure 6
The effect of E1R on scopolamine-induced impairment of spontane-
ous alternation behaviour in the Y-maze test in mice. Mice were
injected with E1R (10 mg·kg−1 i.p.) 60 min before the training
session. Scopolamine (0.5 mg·kg−1, s.c.) was administered 40 min
before the training session. The effect of E1R was antagonized by the
administration of the selective sigma-1 receptor antagonist NE-100
(2 mg·kg−1) 20 min before E1R. The data are presented as the mean
% of alternation behaviour ± SEM; n = 14–16. #P < 0.05 of the
scopolamine-treated group versus the saline group, *P < 0.05 versus
the scopolamine-treated group, and $P < 0.05 versus the E1R-treated
group.
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the sigma-1 receptor modulatory activity of E1R in vivo.
Therefore, we propose that the cognition-enhancing effects
of E1R may involve modulation of the activity of endogenous
agonists of sigma-1 receptors. To date, memory enhance-
ments have been observed only for endogenous sigma-1
receptor agonists including dehydroepiandrosterone and its
sulphate (Roberts et al., 1987; Flood et al., 1988); exogenous
sigma-1 receptor agonists induce memory enhancements
only in amnesia models.
The neurosteroids are considered to be the most probable
endogenous sigma-1 receptor ligands (Cobos et al., 2008;
Niitsu et al., 2012). Neurosteroids such as pregnenolone and
dehydroepiandrosterone are known to bind to sigma-1 recep-
tors under physiological conditions, and sigma-1 receptors
constitute one of the key targets in their trophic, neuromodu-
latory and behavioural effects (Su et al., 1988; Monnet and
Maurice, 2006). Pregnenolone, dehydroepiandrosterone and
other nonsteroidal sigma-1 receptor agonists, affect the learn-
ing and memory processes in cholinergic and NMDA
receptor-dependent models of amnesia and aging (Maurice
et al., 2001; Monnet and Maurice, 2006). A significant corre-
lation between the levels of pregnenolone in the hippocam-
pus of aged rats and memory performance has been observed
(Robel et al., 1995). Interestingly, sigma-1 receptor density is
frequently preserved during aging (van Waarde et al., 2011).
Apart from E1R, few positive allosteric modulators of
sigma-1 receptors have been described (Cobos et al., 2008;
Guo et al., 2013). Phenytoin has been reported to decrease
motor activity in mice (Poncelet et al., 1984), reduce increases
in extracellular K+ concentrations (Nobile and Lagostena,
1998) and inhibit both Na+ (Rush and Elliott, 1997) and
T-type Ca2+ currents (Todorovic and Lingle, 1998). Unlike
E1R, treatment with phenytoin triggered memory impair-
ment during the PA task (Reeta et al., 2009). Consequently,
we examined the effects of E1R on locomotor activity using
the open-field test. Unlike phenytoin, E1R did not affect
locomotion at doses up to 100 mg·kg−1 (Table 1) and did not
influence Na+ and K+ channels in pharmacological profiling
assays (Supporting Information Table 1). Therefore, E1R is the
first reported positive allosteric modulator of sigma-1 recep-
tors that enhances cognition without affecting locomotor
activity.
Recently published reviews suggest a renewed interest in
sigma-1 receptors (Maurice and Su, 2009; Kourrich et al.,
2012) and a need for further research in this field (Abate,
2012). Therefore, because E1R has unique pharmacological
and behavioural profiles as well as low toxicity, it may
become a useful tool for detailed studies of sigma-1 receptors
and an emerging drug target in CNS pharmacology. The
pharmacological profile of E1R may be of particular rel-
evance for the development of new therapies for the treat-
ment of cognitive disorders, including those that are
associated with neurodegenerative diseases. In support of
this idea, some of the currently approved Alzheimer’s disease
medications, such as the cholinesterase inhibitor donepezil,
are potent sigma-1 receptor ligands (Kato et al., 1999). The
symptomatic and potential neuroprotective effects of done-
pezil in Alzheimer’s disease (Francis et al., 2005) may arise
from both direct and indirect cholinergic mechanisms, as
well as an interaction with the sigma-1 receptor, as this
receptor provides neuroprotection against glutamate and
amyloid toxicities.
The memory-improving effects of E1R in both drug-naïve
and scopolamine-treated mice in the PA test are of particular
interest because of the piracetam-like structure of E1R. Many
racetams share piracetam’s nootropic properties in several
mammalian species ranging from rodents to humans (Froestl
and Maitre, 1989; Gouliaev et al., 1995; Malykh and Sadaie,
2010). Racetams enhance performance during various learn-
ing and memory tasks, particularly in the PA test in mice and
rats (Mondadori et al., 1989; Krylova et al., 1991; Zvejniece
et al., 2011). Piracetam and its derivatives are known to alle-
viate memory deficits caused by scopolamine and other
amnesic drugs, as well as electroconvulsive shock and
hypoxia (Malykh and Sadaie, 2010; Zvejniece et al., 2011).
Recent studies have indicated that phenylpiracetam and its
most active R-enantiomer (R-phenylpiracetam) possesses
both memory-improving activity in the PA task and motor-
stimulant properties in the open-field test (Tiurenkov et al.,
2007; Zvejniece et al., 2011). E1R is a close structural analogue
of these two compounds, which differ in structure by only
one methyl group (Kalvins et al., 2011; Zvejniece et al., 2011;
Veinberg et al., 2013), suggesting that E1R may exhibit similar
behavioural effects. However, our present data show that
although E1R exhibited cognition-enhancing activity, similar
to that of R-phenylpiracetam, E1R did not affect performance
in the open-field test at doses up to 100 mg·kg−1. Therefore,
even minor structural alterations may contribute to rather
significant differences in the pharmacological activity of
piracetam-like compounds.
Table 1
The effects of E1R on moved distance in the open-field test
Dose (mg kg−1 i.p.)
Moved distance, cm (4 min)−1
30 min 60 min 120 min 180 min 240 min
Saline 1124 ± 121 623 ± 136 578 ± 126 436 ± 125 398 ± 70
E1R 1 1402 ± 101 871 ± 111 688 ± 82 559 ± 84 626 ± 110
E1R 10 1026 ± 65 640 ± 73 472 ± 60 406 ± 62 359 ± 58
E1R 100 1076 ± 78 648 ± 71 470 ± 75 450 ± 87 458 ± 35
Data represent the means ± SEM; n = 10.
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Consequently, E1R is a unique racetam compound
because it displays cognition enhancements linked to posi-
tive allosteric sigma-1 receptor modulation. To our knowl-
edge, E1R is the first piracetam derivative reported to
modulate sigma-1 receptors, prompting further studies to
elucidate the exact molecular mechanisms and possible
structure-activity relationships underlying its memory-
improving effects.
In conclusion, E1R is a novel 4,5-disubstituted pira-
cetam derivative that enhanced cognition and alleviated
scopolamine-induced cholinergic dysfunction, without
affecting locomotor activity in mice. These effects are related
to the positive allosteric modulation of sigma-1 receptors by
E1R. Therefore, E1R may be interesting as both a novel tool
for studying sigma-1 receptor pharmacology and a novel drug
candidate for treating cognitive disorders.
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